Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 91 AL 105

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.

New and emerging treatments for Alzheimer's disease

Corbett A, Smith J, Ballard C.

Expert Rev Neurother. 2012 May;12(5):535-43. doi: 10.1586/ern.12.43.

Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease

Eckert GP, Renner K, Eckert SH, Eckmann J, Hagl S, Abdel-Kader RM, Kurz C, Leuner K, Muller WE.

Mol Neurobiol. 2012 Aug;46(1):136-50. doi: 10.1007/s12035-012-8271-z. Epub 2012 May 3.

A review: inflammatory process in Alzheimer's disease, role of cytokines

Rubio-Perez JM, Morillas-Ruiz JM.

ScientificWorldJournal. 2012;2012:756357. doi: 10.1100/2012/756357. Epub 2012 Apr 1.

Is RAGE still a therapeutic target for Alzheimer's disease?

Deane RJ.

Future Med Chem. 2012 May;4(7):915-25. doi: 10.4155/fmc.12.51.

Gantenerumab for the treatment of Alzheimer's disease

Delrieu J, Ousset PJ, Vellas B.

Expert Opin Biol Ther. 2012 Aug;12(8):1077-86. doi: 10.1517/14712598.2012.688022. Epub 2012 May 15.

Anti-apoptotic and anti-oxidative mechanisms of minocycline against sphingomyelinase/ceramide neurotoxicity: implication in Alzheimer's disease and cerebral ischemia

Chen SD, Yin JH, Hwang CS, Tang CM, Yang DI.

Free Radic Res. 2012 Aug;46(8):940-50. doi: 10.3109/10715762.2012.674640. Epub 2012 May 28.

Review of theoretical studies for prediction of neurodegenerative inhibitors

Prado-Prado F, García I.

Mini Rev Med Chem. 2012 Jun;12(6):452-66. doi: 10.2174/138955712800493780.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2012 May 16;5(5):CD005380. doi: 10.1002/14651858.CD005380.pub4.

Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease

Frieden C, Garai K.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):8913-8. doi: 10.1073/pnas.1207022109. Epub 2012 May 21.

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections

Danysz W, Parsons CG.

Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x.

Modulating metals as a therapeutic strategy for Alzheimer's disease

Hung LW, Barnham KJ.

Future Med Chem. 2012 May;4(8):955-69. doi: 10.4155/fmc.12.32.

Manipulation of microglial activity as a therapy for Alzheimer's disease

Tan B, Choi RH, Chin TJ, Kaur C, Ling EA.

Front Biosci (Schol Ed). 2012 Jun 1;4(4):1402-12. doi: 10.2741/s342.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias